Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
KNSA
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Last trade$94.57
Day change+$0.34 (+0.36%)
Day range$93.32 – $95.47
Volume202,073
Market cap$7.40B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.4B
Price / earnings
67.57×
Price / book
10.43×
Price / sales
7.83×
EV / sales
7.85×
EV / EBITDA
56.12×
Profitability
Earnings per share
$1.39
Return on assets
11.14%
Return on equity
15.43%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.15×
Current ratio
3.91×
Quick ratio
3.35×
Cash ratio
0.43×
Cash flow
Price / cash flow
37.24×
Price / free cash flow
37.55×
Free cash flow
$197.2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KNSA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$285.97M
$243.6M
$214.27M
$202.13M
$180.86M
$156.8M
$137.79M
$122.54M
Cost of revenue
$27.76M
$23.57M
$20.8M
$20.95M
$20.26M
$18.6M
$17.87M
$17.9M
Gross profit
$258.21M
$220.03M
$193.47M
$181.18M
$160.6M
$138.19M
$119.92M
$104.64M
Selling, general and administrative
$65.36M
$63.87M
$61.15M
$56.78M
$49.1M
$46.86M
$43.53M
$40.54M
Research and development
$32.79M
$40.9M
$27.48M
$34.61M
$24.17M
$18.75M
$19.33M
$35.22M
Total operating expenses
$203.98M
$192.83M
$164.2M
$161.41M
$136.58M
$118.03M
$106.65M
$123.94M
Operating income
$54.24M
$27.19M
$29.27M
$19.77M
$24.02M
$20.16M
$13.27M
-$19.3M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$59.06M
$31.15M
$32.68M
$23.27M
$27.16M
$22.88M
$15.57M
-$16.98M
Income taxes
$11.71M
$5.71M
$10.09M
$9.07M
$8.72M
$5.05M
$7.03M
-$8.09M
Net income
$47.35M
$25.43M
$22.59M
$14.2M
$18.44M
$17.83M
$8.54M
-$8.89M
Net income attributable to common shareholders
$47.35M
$25.43M
$22.59M
$14.2M
$18.44M
$17.83M
$8.54M
-$8.89M
EBITDA
$54.73M
$27.67M
$29.74M
$20.24M
$24.41M
$20.52M
$13.62M
-$18.9M
Basic earnings per share
$0.61
$0.33
$0.30
$0.19
$0.25
$0.24
$0.12
-$0.12
Diluted earnings per share
$0.56
$0.30
$0.27
$0.17
$0.23
$0.23
$0.11
-$0.12
Recent news
Company coverage with links to the original publishers.
Kinikska Pharmaceuticals International (KNSA), a biopharmaceutical company focused on cardiovascular therapies, is highlighted as a strong momentum stock. The company holds a #3 (Hold) Zacks Rank with a B VGM Score and B Momentum Style Score. Two analysts revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $1.30 per share for fiscal 2026. Shares have risen 21% over the past four weeks, and the company boasts an average earnings surprise of +20.9%.
The Nasdaq-100 fell nearly 5% on Friday, marking its third 10% correction this year, though it has nearly doubled over three years. The article advises investors to stay invested during market volatility through strategies like dollar-cost averaging and diversification. Key earnings this week include Apple, Shopify, AMD, and Berkshire Hathaway. Kiniksa Pharmaceuticals' heart drug Arcalyst is projected to become a blockbuster with $1B+ sales. Investors should focus on long-term plans rather than election-driven trading.
Kiniksa Pharmaceuticals reported Q2 2026 net product revenue of $243.6 million for ARCALYST, representing 55% year-over-year growth, and raised full-year 2026 guidance to $980-995 million. The company announced positive Phase 2 data for KPL-387 showing rapid pain and inflammation reduction, with the pivotal Phase 3 PASTORALE trial now enrolling patients. KPL-1161 development is on track for Phase 1 initiation by end of 2026. The company maintains a strong balance sheet with $525.9 million in cash and no debt.
Kinikska Pharmaceuticals International (KNSA) surged nearly 24% after reporting strong Q1 2026 earnings that beat analyst expectations. Revenue from its drug Arcalyst reached $214 million (vs. $138 million year-ago), and net income more than doubled to $22.6 million. The company raised its full-year Arcalyst sales guidance to $930-945 million, driven by recent approval for heart disorder pericarditis.
Kiniksa Pharmaceuticals received FDA Orphan Drug Designation for KPL-387, a monoclonal antibody targeting pericarditis treatment, with potential for monthly subcutaneous self-injection.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.